Skip to NavigationSkip to content

GSK to make redundancies at plant in Stevenage

Published on 17/04/19 at 09:34am

GlaxoSmithKline are set to make redundancies at their site in Stevenage. The move comes as the firm takes “a new approach to research and development,” in focusing more strongly on “transformational medicines.”

As explained by a GSK spokesperson at the Gunnels Wood Road site: “Since we announced our new approach to research and development in 2018, the future direction of our portfolio has become clearer, prioritising innovation and moving towards delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science.”

A company spokesperson said just “a small number of roles” would be directly impacted.

“We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK's R&D operations to grow overall with increased investment.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches